Full Text Article

Introduction

Heart function is adversely affected by high aldosterone levels, as demonstrated by numerous basic studies and significant clinical trials [1-3]. Many harmful effects of aldosterone include the production of inflammation, fibrosis, and oxidative stress [4,5].

Furthermore pro-arrhythmic is aldosterone [6]. This is caused by direct impacts on many ionic currents [7] as well as indirect systemic effects including changes in potassium levels or development of fibrosis [6,8].

These modifications are linked to abnormalities in the ECG, including lengthening of recognized risk factors for sudden cardiac death [6,9,10] include the QT interval and increased QT dispersion [6-8]. According to [11], aldosterone antagonists also stop QT prolonging and dispersion as well as the electrical remodeling that occurs in rat hearts after myocardial infarction.

After myocardial infarction, in both systolic and diastolic heart failure [3,12,13], and in hypertension, elevated cardiac aldosterone levels have been found. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacious and Survial Study (EPHESUS) and the Randomized Aldactone Evaluation Study (RALES), two sizable investigations, have demonstrated that inhibition of Patients with heart failure had lower mortality and morbidity when they have a mineralocorticoid receptor [13,14]. Still up for debate, though, is where the rise in cardiac aldosterone came from [15,16].

On the one hand, there is proof that the genes responsible for producing aldosterone in cardiac cells are expressed [17,18], regardless of the amount of the hormone in the blood [19-23]. However, some data indicate that pathology-driven higher levels may reflect greater binding or uptake from the plasma, rather than local synthesis, given on the relatively low cardiac levels of aldosterone [2,3,16,24,25].

A portion of the contentious data could stem from variations in the species/strains examined [15,16]; alternatively, it could be because cardiac cells don't normally synthesize aldosterone and only do so in pathological circumstances [15;16,22,26]. Diabetes is a significant pathology where aldosterone may be involved. The prevalence of diabetes is rising quickly [27,28].

This condition can cause major cardiovascular problems, such as the emergence of a unique cardiomyopathy. According to [29], mechanical and electrical damage result in a high diabetes is an independent predictor of death, independently to preexisting hypertension or ischemic heart disease, due to the prevalence of heart failure [30]. Increased plasma aldosterone may be linked to diabetes [29,31].

Aldosterone receptor inhibition has been shown to improve heart function. There is evidence to show that high levels of aldosterone and hyperglycemia amplify each other's harmful effects [5,32]. Attenuation of K+ currents, which are responsible for the repolarization of the ventricular action potential, is one of the electrophysiological alterations associated with diabetes [33,34]. The prolongation of the QT interval in the diabetic human ECG (Ewing) may be partially explained by the ensuing prolongation of the action potential [35,36].

Numerous kinds of diabetes-related arrhythmias have known substrates in the form of QT lengthening and increased QT dispersion [36,37]. In rat and human cardiac myocytes, diabetes has also been demonstrated to increase angiotensin II [28,38,39]. Diabetes may cause an elevated risk of sudden cardiac death due to an increase in angiotensin II [10,40,41]. This could be partly due to an inhibition of K+ currents, as in the type I diabetes rat caused by streptozotocin (STZ) [42] or the diabetic rabbit induced by alloxan [43]. This attenuation could be caused in part by due to increased levels of angiotensin II, which have been demonstrated to directly attenuate several K+ current types [44,45]. Angiotensin II induces oxidative stress, which has an impact on K+ currents [46]. Our previous study revealed a key gender difference: in myocytes from diabetic females, angiotensin II levels are not elevated [42]. As a result, there is less oxidative stress and less attenuation of K+ currents than in diabetic males. Higher levels of angiotensin II can be beneficial because it is a significant regulator of aldosterone synthesis [47], could result in elevated levels of aldosterone. Nevertheless, angiotensin II may not always be necessary for an increase in aldosterone levels [6]. According to recent reports [48], angiotensin II receptor knockout mice may exhibit persistent cardiac aldosterone synthesis. Additionally, heart failure patients may have elevated plasma aldosterone levels despite complete inhibition of angiotensin-converting enzyme (ACE).

Discussion

Overview of the Outcomes

To the best of our knowledge, our findings are the first to demonstrate the role aldosterone plays in regulating cardiac K+ currents and oxidative stress in the context of diabetes. The current work demonstrates that aldosterone-dependent K+ current attenuation and action potential extension occur as part of the diabetic heart pathology, which is consistent with the reported attenuation of K+ currents by exogenous (in vitro) aldosterone [49]. Our findings demonstrate a gender-specific increase in currents that is attained through the inhibition of aldosterone synthase with FAD286 and the inhibition of mineralocorticoid receptors with spironolactone. Additionally, both substances lessen oxidative stress in the ventricular cells of male diabetic rats. An important factor in the gender-dependent impacts appears to be sex hormones. It appears that female sex hormones prevent K+ current regulation by aldosterone suppression, since diabetic male and female ovariectomized cells exhibit comparable responses. In contrast, while spironolactone effects are missing in male orchiectomized diabetics, androgens in males appear to contribute to the present attenuation by aldosterone. Lastly, the data demonstrate that cellular aldosterone is also dramatically decreased by a considerable fall in angiotensin II concentration caused by prolonged ACE inhibition. Nevertheless, spironolactone continues to increase K+ currents, indicating that aldosterone may have some effects that are not dependent on angiotensin II.

Study limitations

Results from rat models must be applied with extreme caution to humans. This study's complement of K+ currents that determine repolarization differs in humans and rats, with the human ventricle having a greater prominence of the slow and fast currents IKr and IKs. Nevertheless, a type I diabetic rabbit model likewise exhibits attenuation of both these currents [43]. Furthermore, there are a number of similarities between the STZ rat model and human diabetes. These include the increase in cardiac angiotensin II levels in rats [38] and humans [39], as well as the prolonging of the QT interval in rat [50] and human [36] ECGs. It's interesting to note that angiotensin II may reduce IKs [44], highlighting potential similarities between renin-angiotensin-aldosterone system activity and electrophysiological abnormalities in humans and rats. The tiny levels of cellular aldosterone and angiotensin II, which cause variation in ELISA quantification, are another research constraint. Variability in the amount of changes in currents and oxidative stress is also caused by further variation in the degree of disruption in these chemicals' levels. However, the combination of techniques, including oxidative stress, ELISA, and current measurements, helps to partially offset this variability. Moreover, the impossibility of full quantification hinders research on the angiotensin II-independent aldosterone action because even with total ACE inhibition, there may be more channels for the production of angiotensin II, which could raise levels of aldosterone.However, our findings indicate that functionally meaningful amounts of aldosterone are still able to influence K+ currents in the diabetic heart even after extremely significant ACE suppression. Lastly, while type II diabetes accounts for the majority of cases of diabetes in humans, our work used a type I diabetes model. However, recognition of the overlap between the two categories is expanding (see, for instance, Severson, 2004). Thus, hyperglycemia, pancreatic β cell secretory abnormalities, oxidative stress, comparable ECG alterations, and angiotensin system activation are shared by both kinds of diabetes.

Meaning and Interpretation

Our findings are consistent with a growing understanding of the detrimental effects of high aldosterone in cardiac pathologies, including diabetes [5] and heart failure [4,1]. Numerous studies that highlight the advantages of mineralocorticoid antagonists-which are now widely used as a therapeutic intervention-also highlight the harmful effects of increased aldosterone [14,51]. These positive outcomes occur regardless of the reduction in hypertension brought about by these substances [51]. Because it might worsen the damage caused by hyperglycemia, an increase in testosterone may be especially dangerous in people with diabetes [5]. On the other hand, hyperglycemia can make the negative effects of aldosterone worse [32,52]. Our findings imply that the known pro-arrhythmic characteristics of diabetic complications may be influenced by the electrophysiological effects of aldosterone, specifically the prolongation of the QT interval in the ECG and the attenuation of outward K+ currents [8,9,11,37,40,49]. Therefore, aldosterone receptor blockage by mineralocorticoid antagonists is advantageous for diabetic patients [5]. According to our research, some of these advantages might be associated with an absence of aldosterone's arrhythmogenic effects. Additional research demonstrates that long-term suppression of the aldosterone receptor impedes the decrease in outflow currents that occurs after myocardial infarction in addition to fixing the ECG's QT anomalies [11].

Cellular Aldosterone and Plasma

While the evidence for extra-adrenal synthesis of aldosterone [17,23,26] is still controversial, the elevation of plasma aldosterone in cardiac pathology appears established [14,31,48,53,54]. Our findings verify that male diabetic rats have higher plasma levels of aldosterone. Male diabetics also exhibited a tendency for cellular aldosterone to rise. Nevertheless, as its source can be increased absorption, an increase in cellular aldosterone does not necessarily signify improved cellular synthesis [25]. Which demonstrate current augmentation with the aldosterone synthase inhibitor FAD286, unmistakably indicates increased cellular production under diabetic circumstances, since isolated single cells are used to measure these effects. The decrease in oxidative stress in isolated cells after exposure to FAD286 independently confirms this. In diabetics, an increase in either plasma or cellular aldosterone would be adequate to reduce potassium currents. According to [49] aldosterone may reduce the transient K+ current in normal rat cells by altering the synthesis of channel protein, which is triggered by variations in calcium levels. These effects don't show up until 48 hours following incubation. It is likely that the increased levels of aldosterone in cardiac cells seen in this study have comparable effects on K+ channels. Consequently, only after more than five hours do Ipeak and Isus increase when aldosterone production or activity is suppressed, suggesting that, similar to quinapril, an ACE inhibitor, fresh channel protein synthesis is necessary [34].

Disparities in Gender

The lack of effect of FAD286 or spironolactone on K+ currents in the cells from these rats is consistent with the fact that neither cellular nor plasma aldosterone increases in female diabetic rats. This finding is in line with our previous research [33,34] which shown variations in the response to ACE inhibition and oxidative stress between genders [35]. It was suggested that estrogen's inhibition of the RAS was the cause of this discrepancy [55]. Our findings imply that oestrogen also suppresses the production of aldosterone, as evidenced by the return of spironolactone-induced augmentation of K+ currents in female diabetic ovariectomized patients. On the other hand, it has been proposed that androgens cause or worsen a number of gender disparities [55,56]. It has been demonstrated that androgens activate certain RAS components [55,57]. Our findings are the first to imply that some gender differences originate from androgen effects on the RAS rather than (or in addition to) direct effects on K+ currents themselves as in [56]. of our study shows that spironolactone has no effect on K+ currents in orchiectomized rats. It is therefore suggested that androgens play a role in the acquired sensitivity of K+ currents to aldosterone suppression in males with diabetes. The creation of diabetes appears to have a lesser (or missing) effect of elevating aldosterone in orchiectomized rats in the absence (or severe reduction) of androgens, so that spironolactone no increases K+ currents for longer.

Aldosterone's Dependency on Angiotensin II

Numerous alterations in heart structure and function are brought about by diabetes [29]. The two main triggers for aldosterone increase are the RAS activation and the rise in angiotensin levels (caused by hyperglycemia). Experiments involving prolonged in vivo ACE inhibition, which results in a significant decrease in aldosterone, provide evidence for this Compared to diabetic animals not receiving quinapril in vivo; the extremely significant reduction in angiotensin II by in vivo quinapril makes K+ currents in cells from diabetic rats insensitive to further in vitro quinapril. Even Nevertheless, after angiotensin II suppression, aldosterone receptor blockage substantially increases both K+ currents It is plausible that minute quantities of leftover angiotensin-II all of the aldosterone's side effects that are still there after quinapril medication. However, in other investigations, including those involving mice that had the angiotensin II receptor 1A removed [26] and complete suppression of ACE, it was discovered that the rise of plasma aldosterone persisted. In the latter instance, aldosterone synthesis may be mediated by additional angiotensin II receptors or ACE-independent angiotensin II synthesis. Studies demonstrating additive ameliorative effects of angiotensin II and aldosterone inhibition offer more evidence in favor of angiotensin II-independent aldosterone action [51]. Aldosterone production that is angiotensin II-independent may be caused by increased sympathetic activity [58] or raised endothelin-1 levels. Another autocrine modulator that we previously demonstrated to be involved in the modulation of K+ current is endothelin-1 [34]. Our unpublished results indicate that endothelin-1 was elevated in the cells of STZ diabetic rats, and this may be one reason for the elevated aldosterone levels. Our findings, which demonstrate that aldosterone affects K+ currents in the presence of diabetes without the angiotensin II impact, are significant because they shed light on the intricate regulation of K+ currents. Therefore, there are several ways to repair anomalies in K+ current and potentially QT [11]. The investigation of the connections between variations in the levels of various autocrine modulators, which can happen without alterations in plasma concentrations [17], which could have significant clinical ramifications. ACE inhibitors are among the frequently used medications that have negative side effects associated with them [59,60]. Therefore, a logical design of therapeutic options for correcting or preventing diabetic problems will be made possible by knowledge of the role and interrelationship of autocrine modulators.

In Summary

Our study shows that elevated cardiac and plasma aldosterone levels cause dysfunction in the diabetic male rat heart. Both arrhythmogenesis and mechanical impairment may be influenced by the way that aldosterone lengthens the action potential and decreases K+ currents. While androgens amplify these effects, estrogen lessens them. Thus, the decrease in aldosterone's localized cardiac effects may account for at least some of the benefits of aldosterone blocking in diabetic patients. Through effects on repolarizing currents, an improvement in repolarizing currents and action potential shortening may lower the frequency of cardiac arrhythmias and indirectly boost contractile activity.

Conflict of Interest

The authors state no conflict of interest.